Research programme: farnesyl transferase inhibitors - Abbott LaboratoriesAlternative Names: A 409100; ABT 100; Farnesyl transferase inhibitors research programme - Abbott
Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Imidazoles
- Mechanism of Action Farnesyltranstransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Transplant rejection